Orthopedic med tech innovator Camber Spine Technologies, LLC has announced a new addition to its growing team. In early July 2021, the company named Greg Reiswig its new Vice President of Sales for the Western United States.
Greg Reiswig New VP of Sales at Camber Spine
Reiswig has more than 30 years of experience in medical technology and device sales, including 16 years of executive sales management in both the United States and Mexico. His career experience began at Smith & Nephew. Reiswig also has professional experience at Kyphon, DePuy and US Spine. He has served as Vice President of Sales at Medysset and as President of Desert Medical Specialists.
“I was drawn to Camber Spine due not only to its highly innovative products, but also the strong team who makes the company what it is today,” Reiswig stated. “Camber’s devoted team and corporate management strive every day to produce the highest quality products in an extremely competitive spinal device market. For example, with its game changing OLIF portfolio, Camber has become a procedural innovator for the anterior column space. I’m proud to become part of a company dedicated to developing innovative solutions to complex surgical needs. I am looking forward to building a future together with Camber Spine by expanding the growth of these great products throughout the Western region.”
Camber Global Vice President of Sales and Marketing Max Painter told OTW, “Greg has an ideal blend of experience and expertise that we feel make him a great fit to head up our Western region. He’s a proven sales leader who knows how to develop new markets and exceed revenue goals. His ability to manage winning sales teams while forging strong surgeon and distributor relationships is a fantastic asset. He is the ideal addition to our growing team to ensure Camber sets new sales records in the Western region.”
Based in King of Prussia, Pennsylvania, Camber Spine creates surgeon-designed technology for use in treatment of complex spinal pathology. The company is focused on innovation and high quality production through state-of-the-art manufacturing processes and the newest capabilities in 3-D printing.
Camber utilizes a team approach where employee specialists are in close contact. Located close to Philadelphia, the company’s 27,000 square foot Camber Spine Science and Technology building is home to sales, marketing, engineering, design and development teams.
The headquarters building also includes a mechanical test lab with a full prototype shop mechanical testing laboratory and an expanded double cadaver laboratory. Camber currently touts over 28 active or issued patents, including two Intellectual Property (IP) protected device platforms for support of faster spinal fusion and patient recovery: ENZA® (MIS Integrated Interbody) spinal fusion implants and SPIRA® OA (Open Architecture 3D printed) spinal fusion and orthopedic implants.
Camber Spine also recently received a Orthopedics This Week 2020 Best New Spine Technology Award for its complex spinal treatment system, the OLIF (oblique lateral interbody fusion) Retractor System.
Painter told OTW, “For Camber Spine, 2021 continues to be a landmark year in our development. Our national rollout of the VARIANT retractor system required to perform Oblique Lateral Interbody Fusion (OLIF) surgeries continues to exceed expectations.”
“Our product pipeline for the remainder of the year remains robust as we plan to execute two additional product launches. We continue to expand the SPIRA 3-D printed interbody line by launching SPIRA into the PLIF and TLIF interbody markets with the SPIRA P and T implant lines. In addition, we will add to the ENZA product line with the launch of ENZA C, a game changing cervical implant capitalizing on ENZA’s integrated blade technology. We are on track for 2021 to be the strongest year in the company’s history.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.